Paediatrics (RCH) - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 8 of 8
  • Item
    Thumbnail Image
    A novel MYB::PAIP1 oncogenic fusion in pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN) is dependent on BCL2 expression and is sensitive to venetoclax
    Kosasih, HJ ; Healey, G ; Brennan, MS ; Bjelosevic, S ; Sadras, T ; Jalud, FB ; Ibnat, T ; Ng, AP ; Mayoh, C ; Mao, J ; Tax, G ; Ludlow, LEA ; Johnstone, RW ; Herold, MJ ; Khaw, SL ; de Bock, CE ; Ekert, PG (WILEY, 2024-02)
  • Item
    No Preview Available
    Unusual PDGFRB fusion reveals novel mechanism of kinase activation in Ph-like B-ALL
    Sadras, T ; Jalud, FBB ; Kosasih, HJJ ; Horne, CRR ; Brown, LMM ; El-Kamand, S ; de Bock, CEE ; McAloney, L ; Ng, APP ; Davidson, NMM ; Ludlow, LEA ; Oshlack, A ; Cowley, MJJ ; Khaw, SLL ; Murphy, JMM ; Ekert, PGG (SPRINGERNATURE, 2023-04)
  • Item
    Thumbnail Image
    LGG-58. Understanding the transcriptional heterogeneity of pediatric low-grade gliomas and its implication for tumor pathophysiology
    Boisvert, M ; Perera, AA ; Condurat, AL ; Jeang, J ; Tsai, JW ; Novikov, D ; Zhou, K ; Chacon, M ; DiGiacomo, J ; Kumbhani, R ; Wang, D ; Taylor, MD ; Hansford, JR ; Ludlow, L ; Jabado, N ; Ligon, KL ; Beroukhim, R ; Bandopadhayay, P ; Jones, DTW (Oxford University Press (OUP), 2022-06-03)
    Abstract Pediatric low-grade gliomas (pLGGs) are the most frequent brain tumors in children and comprise a heterogeneous group of tumors with different locations, histologic subtypes, ages at presentation, and clinical behavior. Tumors frequently respond to treatment with chemotherapy or surgical removal, but they can regrow after a period of quiescence, requiring further therapy. Thus, a deeper understanding of the molecular processes involved in these tumors is required to develop therapeutic strategies that are effective against their disease mechanisms. To better understand the cellular behaviors of this heterogenous group of tumors, we have employed single-cell and single-nuclei RNA sequencing technologies to analyze a large-scale dataset (>250,000 cells) of pLGGs. Analysis of this data identified a heterogenous population of cell types and cell states, detecting mature and progenitor-like astrocytes and oligodendrocytes, as well as cells exhibiting senescence or cycling programs. Moreover, we identify a significant immune infiltrate, comprised primarily of microglia. In addition to heterogeneity within pLGG tumors, heterogeneity between LGG subtypes represents another layer that stratifies pLGG biology. We performed a compositional analysis of the cell types present in these tumors and compared transcription signatures and gene expression programs across shared cellular populations of histologically and genetically distinct pLGGs. Finally, we optimized our integration and batch correction analyses by using external 293T cells as spike in controls during our single-cell and single-nuclei data generation steps to determine the most suitable method for batch-effect removal. Our analysis of human pLGGs at the single-cell and single-nuclei resolution provides critical insight into the heterogenous biological activities that constitute these tumors.
  • Item
    No Preview Available
    ALLSorts: an RNA-Seq subtype classifier for B-cell acute lymphoblastic leukemia
    Schmidt, B ; Brown, LM ; Ryland, GL ; Lonsdale, A ; Kosasih, HJ ; Ludlow, LE ; Majewski, IJ ; Blombery, P ; Ekert, PG ; Davidson, NM ; Oshlack, A (ELSEVIER, 2022-07-26)
    B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer. Subtypes within B-ALL are distinguished by characteristic structural variants and mutations, which in some instances strongly correlate with responses to treatment. The World Health Organisation (WHO) recognises seven distinct classifications, or subtypes, as of 2016. However, recent studies have demonstrated that B-ALL can be segmented into 23 subtypes based on a combination of genomic features and gene expression profiles. A method to identify a patient's subtype would have clear utility. Despite this, no publically available classification methods using RNA-Seq exist for this purpose. Here we present ALLSorts: a publicly available method that uses RNA-Seq data to classify B-ALL samples to 18 known subtypes and five meta-subtypes. ALLSorts is the result of a hierarchical supervised machine learning algorithm applied to a training set of 1223 B-ALL samples aggregated from multiple cohorts. Validation revealed that ALLSorts can accurately attribute samples to subtypes and can attribute multiple subtypes to a sample. Furthermore, when applied to both paediatric and adult cohorts, ALLSorts was able to classify previously undefined samples into subtypes. ALLSorts is available and documented on GitHub (https://github.com/Oshlack/AllSorts/).
  • Item
    Thumbnail Image
    Chemotherapy-related cardiotoxicity: are Australian practitioners missing the point?
    Conyers, R ; Costello, B ; La Gerche, A ; Tripaydonis, A ; Burns, C ; Ludlow, L ; Lange, P ; Ekert, P ; Mechinaud, F ; Cheung, M ; Martin, M ; Elliot, D (WILEY, 2017-10)
    BACKGROUND: It has long been established that cardiotoxicity occurs as a result of exposure to certain chemotherapeutics, particularly anthracyclines. Historically, clinicians equate cardiotoxicity with a poor prognosis, in a small percentage of patients and deem long-term surveillance as optional. Emerging evidence suggests that anthracycline cardiotoxicity (ACT) is a life-long risk with an incidence approaching 20%. AIMS: To elucidate the incidence of anthracycline cardiotoxicity within a current paediatric oncology survivor cohort. METHODS: Participants were identified through the Haematology-Oncology database at the Royal Children's Hospital, Melbourne. Patients were identified from a retrospective audit of outpatient attendances between January 2008 and December 2015. Patients with a cancer diagnosis exposed to anthracyclines were eligible for the study. Patient demographics and echocardiogram findings were recorded with patients subcategorised according to degree of ACT. More significant ACT defined as fractional shortening (FS) <24% and less significant if FS 24-28% or a decline in baseline ejection fraction of >10%. RESULTS: Two hundred and eighty-six of a total 481 identified patients were eligible for study inclusion. Twenty patients displayed significant ACT with FS <24%. Ten patients had a FS 24-28% and 25 patients with a decline in ejection fraction from baseline of >10%. Overall, 6.6% demonstrated significant cardiac complications, whilst 19.6 % demonstrated some degree of ACT and decline in myocardial function. When stratified for cumulative anthracycline dose, the incidence of severe cardiac dysfunction was 5.1% (<250 mg/m2 ) and 25% (>250 mg/m2 ) CONCLUSION: This study demonstrates, in keeping with modern literature, the higher incidence of anthracycline associated cardiac toxicity and a need for better surveillance and follow up.
  • Item
    No Preview Available
    The Australia and New Zealand Cardio-Oncology Registry: evaluation of chemotherapy-related cardiotoxicity in a national cohort of paediatric cancer patients
    Lapirow, D ; La Gerche, A ; Toro, C ; Masango, E ; Costello, B ; Porello, E ; Ludlow, L ; Marshall, G ; Trahair, T ; Mateos, M ; Lewin, J ; Byrne, J ; Boutros, R ; Manudhane, R ; Heath, J ; Ayer, J ; Gabriel, M ; Walwyn, T ; Saundankar, J ; Forsey, J ; Le, H ; Mason, K ; Celermajer, D ; Downie, P ; Walker, R ; Holland, L ; Martin, M ; McLeman, L ; Diamond, Y ; Marcocci, M ; Donath, S ; Cheung, M ; Elliott, DA ; Conyers, R (WILEY, 2021-02)
    Cancer therapy related cardiac dysfunction (CTRCD) is an area of increasing focus, particularly during the survivorship period, for paediatric, adolescent and adult cancer survivors. With the advent of immunotherapy and targeted therapy, there is a new set of mechanisms from which paediatric and young adult patients with cancer may suffer cardiovascular injury. Furthermore, cardiovascular disease is the leading cause of morbidity and mortality in the survivorship period. The recently established Australian Cardio-Oncology Registry is the largest and only population-based cardiotoxicity database of paediatric and adolescent and young adult oncology patients in the world, and the first paediatric registry that will document cardiotoxicity caused by chemotherapy and novel targeted therapies using a prospective approach. The database is designed for comprehensive data collection and evaluation of the Australian practice in terms of diagnosis and management of CTRCD. Using the Australian Cardio-Oncology Registry critical clinical information will be collected regarding predisposing factors for the development of CTRCD, the rate of subclinical left ventricular dysfunction and transition to overt heart failure, further research into protectant molecules against cardiac dysfunction and aid in the discovery of which genetic variants predispose to CTRCD. A health economic arm of the study will assess the cost/benefit of both the registry and cardio-oncology clinical implementation. Finally, an imaging arm will establish if exercise cardiac magnetic resonance imaging and VO2 max testing is a more sensitive predictor of cardiac reserve in paediatric and adolescent and young adult oncology patients exposed to cardiac toxic therapies.
  • Item
    No Preview Available
    The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia
    Brown, LM ; Lonsdale, A ; Zhu, A ; Davidson, NM ; Schmidt, B ; Hawkins, A ; Wallach, E ; Martin, M ; Mechinaud, FM ; Khaw, SL ; Bartolo, RC ; Ludlow, LEA ; Challis, J ; Brooks, I ; Petrovic, V ; Venn, NC ; Sutton, R ; Majewski, IJ ; Oshlack, A ; Ekert, PG (AMER SOC HEMATOLOGY, 2020-03-10)
    Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, and implementation of risk-adapted therapy has been instrumental in the dramatic improvements in clinical outcomes. A key to risk-adapted therapies includes the identification of genomic features of individual tumors, including chromosome number (for hyper- and hypodiploidy) and gene fusions, notably ETV6-RUNX1, TCF3-PBX1, and BCR-ABL1 in B-cell ALL (B-ALL). RNA-sequencing (RNA-seq) of large ALL cohorts has expanded the number of recurrent gene fusions recognized as drivers in ALL, and identification of these new entities will contribute to refining ALL risk stratification. We used RNA-seq on 126 ALL patients from our clinical service to test the utility of including RNA-seq in standard-of-care diagnostic pipelines to detect gene rearrangements and IKZF1 deletions. RNA-seq identified 86% of rearrangements detected by standard-of-care diagnostics. KMT2A (MLL) rearrangements, although usually identified, were the most commonly missed by RNA-seq as a result of low expression. RNA-seq identified rearrangements that were not detected by standard-of-care testing in 9 patients. These were found in patients who were not classifiable using standard molecular assessment. We developed an approach to detect the most common IKZF1 deletion from RNA-seq data and validated this using an RQ-PCR assay. We applied an expression classifier to identify Philadelphia chromosome-like B-ALL patients. T-ALL proved a rich source of novel gene fusions, which have clinical implications or provide insights into disease biology. Our experience shows that RNA-seq can be implemented within an individual clinical service to enhance the current molecular diagnostic risk classification of ALL.
  • Item
    Thumbnail Image
    Recurrent SPECC1L-NTRK fusions in pediatric sarcoma and brain tumors
    Khuong-Quang, D-A ; Brown, LM ; Wong, M ; Mayoh, C ; Sexton-Oates, A ; Kumar, A ; Pinese, M ; Nagabushan, S ; Lau, L ; Ludlow, LE ; Gifford, AJ ; Rodriguez, M ; Desai, J ; Fox, SB ; Haber, M ; Ziegler, DS ; Hansford, JR ; Marshall, GM ; Cowley, MJ ; Ekert, PG (COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT, 2020-12)
    The identification of rearrangements driving expression of neurotrophic receptor tyrosine kinase (NTRK) family kinases in tumors has become critically important because of the availability of effective, specific inhibitor drugs. Whole-genome sequencing (WGS) combined with RNA sequencing (RNA-seq) can identify novel and recurrent expressed fusions. Here we describe three SPECC1L-NTRK fusions identified in two pediatric central nervous system cancers and an extracranial solid tumor using WGS and RNA-seq. These fusions arose either through a simple balanced rearrangement or in the context of a complex chromoplexy event. We cloned the SPECC1L-NTRK2 fusion directly from a patient sample and showed that enforced expression of this fusion is sufficient to promote cytokine-independent survival and proliferation. Cells transformed by SPECC1L-NTRK2 expression are sensitive to a TRK inhibitor drug. We report here that SPECC1L-NTRK fusions can arise in a range of pediatric cancers. Although WGS and RNA-seq are not required to detect NTRK fusions, these techniques may be of benefit when NTRK fusions are not suspected on clinical grounds or not identified by other methods.